128 related articles for article (PubMed ID: 32596809)
1. 1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)-3-(2-(dimethylamino)ethyl)imidazolidin-2-one (ZX-42), a novel ALK inhibitor, induces apoptosis and protective autophagy in H2228 cells.
Wang L; Xu X; Liu T; Wang J; Shen J; Guo M; Wu Y; Zhai X; Zuo D
J Pharm Pharmacol; 2020 Oct; 72(10):1370-1382. PubMed ID: 32596809
[TBL] [Abstract][Full Text] [Related]
2. The novel ALK inhibitor ZX-29 induces apoptosis through inhibiting ALK and inducing ROS-mediated endoplasmic reticulum stress in Karpas299 cells.
Zhou X; Zhang X; Wu Z; Xu X; Guo M; Zhai X; Zuo D; Wu Y
J Biochem Mol Toxicol; 2021 Mar; 35(3):e22666. PubMed ID: 33140567
[TBL] [Abstract][Full Text] [Related]
3. Correction to: 1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)-3-(2-(dimethylamino)ethyl)imidazolidin-2-one (ZX-42), a novel ALK inhibitor, induces apoptosis and protective autophagy in H2228 cells.
J Pharm Pharmacol; 2023 Apr; 75(5):718. PubMed ID: 36961312
[No Abstract] [Full Text] [Related]
4. 1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)-3-(2-(dimethylamino)ethyl)imidazolidin-2-one (ZX-42) inhibits cell proliferation and induces apoptosis via inhibiting ALK and its downstream pathways in Karpas299 cells.
Chang X; Wang J; Bian J; Liu Z; Guo M; Li Z; Wu Y; Zhai X; Zuo D
Toxicol Appl Pharmacol; 2022 Sep; 450():116156. PubMed ID: 35803438
[TBL] [Abstract][Full Text] [Related]
5. 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-((4-methylpiperazin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)phenyl)pyrimidine-2,4-diamine (WY-135), a novel ALK inhibitor, induces cell cycle arrest and apoptosis through inhibiting ALK and its downstream pathways in Karpas299 and H2228 cells.
Han M; Shen J; Wang L; Wang Y; Zhai X; Li Y; Liu M; Li Z; Zuo D; Wu Y
Chem Biol Interact; 2018 Mar; 284():24-31. PubMed ID: 29458018
[TBL] [Abstract][Full Text] [Related]
6. ZX-29, a novel ALK inhibitor, induces apoptosis via ER stress in ALK rearrangement NSCLC cells and overcomes cell resistance caused by an ALK mutation.
Gou W; Li Z; Xu X; Shen J; Guo M; Zhou X; Zhang X; Wu Y; Zhai X; Zuo D
Biochim Biophys Acta Mol Cell Res; 2020 Jul; 1867(7):118712. PubMed ID: 32224191
[TBL] [Abstract][Full Text] [Related]
7. ZYY-B-2, a novel ALK inhibitor, overcomes resistance to ceritinib by inhibiting P-gp function and induces apoptosis through mitochondrial pathway in ceritinib-resistant H2228 cells.
Gao Y; Liu T; Liu J; Yang Y; Sun K; Li Z; Zhai X; Zuo D
Chem Biol Interact; 2023 Jul; 379():110516. PubMed ID: 37116853
[TBL] [Abstract][Full Text] [Related]
8. A novel ALK inhibitor ZYY inhibits Karpas299 cell growth in vitro and in a mouse xenograft model and induces protective autophagy.
Shen J; Wang J; Du J; Wang L; Zhou X; Chang X; Li Z; Zhai X; Zuo D; Wu Y
Toxicol Appl Pharmacol; 2019 Nov; 383():114781. PubMed ID: 31618659
[TBL] [Abstract][Full Text] [Related]
9. Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.
Chen Y; Ma G; Su C; Wu P; Wang H; Song X; Yu Q; Zeng A; Zhou S
Anticancer Drugs; 2018 Nov; 29(10):935-943. PubMed ID: 30074936
[TBL] [Abstract][Full Text] [Related]
10. [Effect and mechanism of silibinin on the inhibition of ALK positive NSCLC cells by sensitizing crizotinib].
Lin CC; Lu CH; Pan YH; Jiao L; Chen HY; Li L; He Y
Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):650-656. PubMed ID: 28926892
[No Abstract] [Full Text] [Related]
11. Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing a sulfoxide moiety as anaplastic lymphoma kinase (ALK) inhibition agents.
Wu F; Yao H; Li W; Zhang N; Fan Y; Chan ASC; Li X; An B
Bioorg Med Chem Lett; 2021 Sep; 48():128253. PubMed ID: 34245852
[TBL] [Abstract][Full Text] [Related]
12. ALK inhibition activates LC3B-independent, protective autophagy in EML4-ALK positive lung cancer cells.
Schläfli AM; Tokarchuk I; Parejo S; Jutzi S; Berezowska S; Engedal N; Tschan MP
Sci Rep; 2021 Apr; 11(1):9011. PubMed ID: 33907223
[TBL] [Abstract][Full Text] [Related]
13. EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation.
Li Y; Li Y; Zhang H; Shi R; Zhang Z; Liu H; Chen J
BMC Pulm Med; 2021 Jun; 21(1):190. PubMed ID: 34090412
[TBL] [Abstract][Full Text] [Related]
14. Structure-based optimization identified novel furyl-containing 2,4-diarylaminopyrimidine analogues as ALK/ROS1 dual inhibitors with anti-mutation effects.
Guo M; Zuo D; Zhao T; Li X; Cao J; Qiu Y; Wei S; Zhai X
Eur J Med Chem; 2021 Mar; 214():113259. PubMed ID: 33581554
[TBL] [Abstract][Full Text] [Related]
15. Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance.
Sun N; Ren C; Kong Y; Zhong H; Chen J; Li Y; Zhang J; Zhou Y; Qiu X; Lin H; Song X; Yang X; Jiang B
Eur J Med Chem; 2020 May; 193():112190. PubMed ID: 32179332
[TBL] [Abstract][Full Text] [Related]
16. Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells.
Tanizaki J; Okamoto I; Takezawa K; Sakai K; Azuma K; Kuwata K; Yamaguchi H; Hatashita E; Nishio K; Janne PA; Nakagawa K
Br J Cancer; 2012 Feb; 106(4):763-7. PubMed ID: 22240786
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation N
Xing L; Jing T; Zhang J; Guo M; Miao X; Jiang F; Zhai X
Bioorg Chem; 2018 Dec; 81():689-699. PubMed ID: 30268049
[TBL] [Abstract][Full Text] [Related]
18. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
Mori M; Ueno Y; Konagai S; Fushiki H; Shimada I; Kondoh Y; Saito R; Mori K; Shindou N; Soga T; Sakagami H; Furutani T; Doihara H; Kudoh M; Kuromitsu S
Mol Cancer Ther; 2014 Feb; 13(2):329-40. PubMed ID: 24419060
[TBL] [Abstract][Full Text] [Related]
19. Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC.
Chen Y; Wu J; Wang A; Qi Z; Jiang T; Chen C; Zou F; Hu C; Wang W; Wu H; Hu Z; Wang W; Wang B; Wang L; Ren T; Zhang S; Liu Q; Liu J
Eur J Med Chem; 2017 Oct; 139():674-697. PubMed ID: 28850922
[TBL] [Abstract][Full Text] [Related]
20. Cr(VI)-Induced Autophagy Protects L-02 Hepatocytes from Apoptosis Through the ROS-AKT-mTOR Pathway.
Liang Q; Xiao Y; Liu K; Zhong C; Zeng M; Xiao F
Cell Physiol Biochem; 2018; 51(4):1863-1878. PubMed ID: 30504711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
